Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Post-authorisation efficacy and safety study of imlifidase desensitisation in kidney transplant recipients with positive crossmatch
2021-002640-70Phase 3Active
- Sponsor
- Hansa Biopharma
- Start
- Nov 2021
- Modality
- Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label trial of imlifidase in kidney allograft rejection (3 arms), sponsored by Hansa Biopharma. Primary endpoint: 1-year graft failure-free survival. Started Nov 2021; status: active.
02
Drugs
imlifidase
03
Conditions
kidney allograft rejection
Beyond the preview
Go deeper on 2021-002640-70.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002640-70.